A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
Redeye interview with Anders Hultman CEO, commenting on the Interim Report Q3 2025 IDL Diagnostics (Q3 Interview): Redeye talks with CEO Anders Hultman IDL Diagnostics: CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q3’25 results – November...
Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers,...
